Glioblastoma News and Research

RSS
Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
Study reveals sex-based protein differences across lung cancer types

Study reveals sex-based protein differences across lung cancer types

KAIST study opens a new avenue for treating intractable brain tumors

KAIST study opens a new avenue for treating intractable brain tumors

Blood ketone threshold may help predict weight loss success

Blood ketone threshold may help predict weight loss success

EGFR inhibitors may overcome chemotherapy resistance in glioblastoma treatment

EGFR inhibitors may overcome chemotherapy resistance in glioblastoma treatment

Experimental compound BA-101 overcomes chemotherapy resistance in glioblastoma

Experimental compound BA-101 overcomes chemotherapy resistance in glioblastoma

CAR-T cell therapy shows potential to eliminate aggressive glioblastoma

CAR-T cell therapy shows potential to eliminate aggressive glioblastoma

Dual-target CAR-T therapy shows promise against aggressive brain tumors

Dual-target CAR-T therapy shows promise against aggressive brain tumors

Study uncovers sex-specific immune pathway driving glioblastoma growth

Study uncovers sex-specific immune pathway driving glioblastoma growth

Sugar-coated nanoparticles extend survival in aggressive glioblastoma mouse model

Sugar-coated nanoparticles extend survival in aggressive glioblastoma mouse model

Using the mathematics of quantum mechanics to improve neuroblastoma outcomes

Using the mathematics of quantum mechanics to improve neuroblastoma outcomes

New CellTrap technology reveals how single immune cells attack brain tumors

New CellTrap technology reveals how single immune cells attack brain tumors

Dual-target CAR T therapy triggers broad immune response in brain cancer

Dual-target CAR T therapy triggers broad immune response in brain cancer

Major NIH grant helps establish the Oklahoma Center of ImmunoEngineering

Major NIH grant helps establish the Oklahoma Center of ImmunoEngineering

PhoreMost announces lead oncology program and appoints Chief Medical Officer to support clinical entry

PhoreMost announces lead oncology program and appoints Chief Medical Officer to support clinical entry

New treatment platform delivers full-length mRNA for Duchenne muscular dystrophy

New treatment platform delivers full-length mRNA for Duchenne muscular dystrophy

Drug-filled nanofibers offer potential breakthrough treatment for brain cancer

Drug-filled nanofibers offer potential breakthrough treatment for brain cancer

Vitamin B12 analog targets deadly brain cancer cells

Vitamin B12 analog targets deadly brain cancer cells

Cytokine-armored CAR-T cell therapy successfully attacks aggressive brain tumors in mice

Cytokine-armored CAR-T cell therapy successfully attacks aggressive brain tumors in mice

Fluid viscosity drives mechanical memory and invasion in glioblastoma

Fluid viscosity drives mechanical memory and invasion in glioblastoma

Researchers develop pH and redox-sensitive systems to reduce immunotherapy toxicity

Researchers develop pH and redox-sensitive systems to reduce immunotherapy toxicity

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.